About Syntekabio
Syntekabio is a company based in Sunnyvale (United States) founded in 2009. Syntekabio has raised $11.12 million across 2 funding rounds from investors including Smile Gate Investment, Korea Development Bank Europe and Altos Ventures Management. The company has 61 employees. Syntekabio operates in a competitive market with competitors including NantHealth, BioAge Labs, Perthera, Genedata and Ontoforce, among others.
- Headquarter Sunnyvale, United States
- Employees 61
- Stage Public
- SectorsHealthcare
- Website syntekabio.com/en
- Social LinkedIn Facebook
- Legal Name Syntekabio, Inc.
- Annual Revenue$2.38 M (USD)2736.72as on Dec 31, 2025
- Net Profit-$12.03 M (USD)-140.92as on Dec 31, 2025
- EBITDA-$6.22 M (USD)27.07as on Dec 31, 2025
- Total Equity Funding$11.12M (USD)
in 2 rounds
- Latest Funding Round$7.39M (USD), Post-IPO
Apr 2024
- InvestorsSmile Gate Investment
& 3 more
- Employee Count61
Funding Insights of Syntekabio
Syntekabio has successfully raised a total of $11.12M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $7.39 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.12M
- Total Rounds 2
- Last Round Post-IPO — $7.39M
- First Round $11.12M
(May 2018)
- Investors Count 4
All 2 funding rounds of Syntekabio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $7.39M | Post-IPO | – | – | – |
| May 2018 | $11.12M | Series B | – | Smile Gate Investment, Korea Development Bank Europe | – |
4 investors in total: 4 institutional.
Investors in Syntekabio
Syntekabio has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Smile Gate Investment, Korea Development Bank Europe and Altos Ventures Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investment firm focused on buyouts | – | smilegateinvestment.com | Seoul, South Korea | |
Early-stage companies are funded by this venture capital firm. | – | altos.vc | Menlo Park, United States | |
Operates as a commercial bank providing deposits, loans, and payment services to customers. | 1989 | kdbbank.eu | Budapest, Hungary | |
Venture capital investments are directed toward multiple sectors. | – | korea.yozma.asia | Gangnam, South Korea |
Investor details for Syntekabio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Syntekabio
Syntekabio is a publicly listed company on the KRX with ticker symbol 226330 in South Korea, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Dec 2019
- Listed onKRX: 226330
- Listed entitySYNTEKABIO, INC.
- Exchange sectorTechnology services
- ISINKR7226330009
- Share price1,227.00 KRW (+0.57% on the day) · 2026-10-08
- Market capitalisation29,765,148,027.00 KRW
- EPS (diluted, trailing year)-600.25 KRW
- Volume (last session)59,400
Financials of Syntekabio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 3.43B KRW | -17.38B KRW | -8.98B KRW |
| 2024 | 120.9M KRW | -7.21B KRW | -12.31B KRW |
| 2023 | 123.4M KRW | -11.40B KRW | -10.77B KRW |
| 2022 | 244.0M KRW | -4.51B KRW | -10.55B KRW |
| 2021 | 316.7M KRW | -14.80B KRW | -7.73B KRW |
Detailed financial statements for Syntekabio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Syntekabio
4 dated milestones of Syntekabio across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Syntekabio is founded.
- Funding First funding round of $11.1M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $7.4M.
Competitors of Syntekabio
Syntekabio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NantHealth, BioAge Labs, Perthera, Genedata and Ontoforce, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nanthealth.com | 2007 | El Segundo, United States | $607.58M | 380 | Bioinformatics platforms are provided for cancer treatment identification. | |
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. | |
| perthera.com | 2012 | Mclean, United States | $17.02M | 13 | Molecular cancer profiling is conducted via genomics and proteomics. | |
| genedata.com | 1997 | Basel, Switzerland | – | 66 | Software solutions are developed for drug discovery and life sciences. | |
| ontoforce.com | 2011 | Ghent, Belgium | $9.13M | 31 | Semantic search platform is provided for pharmaceutical and biotech research. | |
| dandelionhealth.ai | 2020 | New York, United States | $15.89M | – | AI-powered real-world data platform is provided for clinical development. | |
| airfinity.com | 2015 | London, United Kingdom | – | 57 | Predictive data analysis software is developed for researchers. | |
| roam.io | 2013 | Dallas, United States | – | – | Cloud-based interactive digital signage solutions are provided for offline retailers. |
Detailed competitors of Syntekabio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Syntekabio
The website of Syntekabio (syntekabio.com) receives about 4.2K visits a month.
- Monthly visits4.2K
▼ 11.9% vs previous month
Websites whose visitors overlap most with Syntekabio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| enamine.net | 100% | 58.1K | #595,309 | View details |
Latest news on Syntekabio
Complete news archive for Syntekabio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Syntekabio
10 companies that operate in the same segment as Syntekabio (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Syntekabio
Syntekabio was founded in 2009 and raised its 1st funding round 9 years after it was founded.
Syntekabio is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
Syntekabio is a funded company, having raised a total of $11.12M across 2 funding rounds to date. The company's 1st funding round was a Series B of $11.12M, raised on May 2018.
Syntekabio has 61 employees.
Annual revenue of Syntekabio is $2.38M as on Dec 31, 2025.
Syntekabio provides life science-specific software and services. It offers General Purpose BioMap Service (GPBS) which is a suite of dynamic workflows. They have developed SQL and BIO DBS, a biomedical database integration tool. BioMaps cover biomedical component maps including Gene, PPI, Pathway-Map, Compound-Map, SNP-Map, and Map 2 Map. The service includes value-added analytics providing multiple mapping such as M2BM (Map to Blockbuster DB Maps), M2AM (Map to Any kinds of diseases, drugs, or functional categories MAPs), M2PM(Map to Public Medline DB Map), IQC (Inter-Query Correlation), etc.
Syntekabio's top competitors include NantHealth, BioAge Labs and Genedata.
Yes, Syntekabio is publicly traded on KRX under the ticker symbol 226330.
Syntekabio has 4 investors. Key investors include Smile Gate Investment, Korea Development Bank Europe, Altos Ventures Management, and Yozma Group Korea.
Syntekabio operates through Syntekabio, Inc..